title: Use of MenACWY-CRM vaccine in children aged 2 through 23 months at increased risk for meningococcal disease: recommendations of the Advisory Committee on Immunization Practices, 2013.
abstract: During its October 2013 meeting, the Advisory Committee on Immunization Practices (ACIP) recommended use of a third meningococcal conjugate vaccine, MenACWY-CRM (Menveo, Novartis), as an additional option for vaccinating infants aged 2 through 23 months at increased risk for meningococcal disease. MenACWY-CRM is the first quadrivalent meningococcal conjugate vaccine licensed for use in children aged 2 through 8 months. MenACWY-D (Menactra, Sanofi Pasteur) is recommended for use in children aged 9 through 23 months who are at increased risk for meningococcal disease, and Hib-MenCY-TT (MenHibrix, GlaxoSmithKline) is recommended for use in children aged 6 weeks through 18 months at increased risk. This report summarizes information on MenACWY-CRM administration in infants and provides recommendations for vaccine use in infants aged 2 through 23 months who are at increased risk for meningococcal disease. Because the burden of meningococcal disease in infants is low in the United States and the majority of cases that do occur are caused by serogroup B, which is not included in any vaccine licensed in the United States, only those infants who are at increased risk for meningococcal disease are recommended to receive a meningococcal vaccine.
authors.forename: Jessica R
authors.initials: JR
authors.lastname: MacNeil
authors.forename: Lorry
authors.initials: L
authors.lastname: Rubin
authors.forename: Lucy
authors.initials: L
authors.lastname: McNamara
authors.forename: Elizabeth C
authors.initials: EC
authors.lastname: Briere
authors.forename: Thomas A
authors.initials: TA
authors.lastname: Clark
authors.forename: Amanda C
authors.initials: AC
authors.lastname: Cohn
mesh_terms: D026683:Advisory Committees; D006801:Humans; D007114:Immunization / Q000592:standards*; D007115:Immunization Schedule; D007223:Infant; D008004:Licensure; D008589:Meningococcal Infections / Q000517:prevention & control*; D022401:Meningococcal Vaccines / Q000008:administration & dosage*; D017410:Practice Guidelines as Topic; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D014481:United States
chemical_list: C556088:MenACWY-CRM vaccine; D022401:Meningococcal Vaccines